Homepage Top Section2

This approval marks the first availability of the therapy in this region. The partnership between Vivus and its marketing partner PharmaAccess aims to equip healthcare providers in the

The approval is intended for those who have a minimum of one F508del mutation or another responsive CFTR gene mutation. The company is working with the National Institute for Health and

Despite a non-binding letter of intent signed in November last year, the companies have mutually decided to discontinue negotiations after failing to meet critical conditions within the set

This investment is part of the company’s plan to broaden its Peptide Platform business and exceed €1bn in sales by 2028. CordenPharma has finalised plans for a new

The move is said to propel the company’s antibody discovery and engineering offerings, and is in line with its current growth plan. Previously known as Distributed Bio, the

This approval covers all indications of the reference products and the biosimilars are anticipated to be available by June 2025 in the country as per the settlement agreement

The oral Factor B inhibitor of the alternative complement pathway is designed for this rare kidney condition with no approved treatments, which significantly impacts young individuals’ lives. The

The designation is designed to accelerate the development and review of medications that show potential to address serious conditions. Candidates with this designation may qualify for an interaction

Carrying the Chinese trade name of Wan Ti Le, the tablets are indicated for individuals who have either insufficient response or cannot tolerate phosphorus binders. They are claimed